All Posts Tagged With: "BAX"
(BAX) Company News for December 14, 2011 – Corporate Summary
• Best Buy (NYSE:BBY) posted Q3 EPS of $0.47 per share, lower than the Zacks Consensus Estimate of $0.51 per share. Revenue for the quarter rose 2% to come in at $12.1 billion
• Share prices of Urban...
(BDX) Becton, Dickinson and Company Hikes Dividend
Becton, Dickinson and Company (BDX) recently declared a quarterly dividend of 45 cents for each common share, representing a hike of 4 cents, or approximately 10%, from the preceding quarter. The company will...
(AAPL) A Busy Week Ahead – Earnings Preview
Earnings Preview 10/14/11
While the earnings season kicked off this past week, only 38 firms reported. The game really gets under way next week, when we will get reports from 336 firms, including 99 members of the S&P 500.
Thus, by the end of the week we...
(AAPL) 2011 Second Quarter Earnings Preview – Detailed
Earnings Preview 7/15/11
Second quarter earnings season is now under way, but things really start to move into high gear next week. There will be 348 firms reporting, and 108 of those are...
(CFN) CareFusion Buying Rowa for $150 Million
Medical technology company CareFusion Corporation (CFN) recently made a deal to buy German medication storage systems maker Rowa GmbH for roughly $150 million.
Rowa, which has customers in 30 countries,...
(BAX) Baxter International Presents Sustainability Report
Baxter International (BAX) recently presented its 2010 Sustainability Report. This was the 12th straight year in which the company has reported on its economic, social and environmental outcomes....
(BAX) Baxter International Gets Favorable Opinion for Drug
Baxter International (BAX) recently revealed that the Committee for Medicinal Products for Human Use (“CHMP”) belonging to the European Medicines Agency (“EMA”) has given a favorable opinion for extending...
(BAX) Baxter International Launches Fresh Initiative To Mark World Hemophilia Day
To mark World Hemophilia Day, Baxter International (BAX) recently reiterated its determination to maintain the standard of care and ensure adequate access to treatment for victims of hemophilia and other bleeding...
(BAX) Baxter International Introduces GLASSIA
Medical products giant Baxter International (BAX) officially commenced the U.S. launch of GLASSIA Alpha 1-Proteinase inhibitor for the treatment of emphysema. The company secured exclusive marketing rights...
(ADBE) Company News for September 22, 2010
• Adobe Systems (NASDAQ:ADBE) reported fiscal third-quarter earnings of 54 cents a share, a nickel higher than anticipated, on revenues, up 42% to $990 million, versus estimates of $985 million. For the current quarter the company expects earnings of 48 cents to 54 cents....
(HSP) Hospira Second Quarter 2010 Earnings Preview
Hospira Inc. (HSP) is scheduled to report its second quarter 2010 results on Wednesday, July 28, before the opening bell. The Zacks Consensus Estimate for the quarter is earnings of 79 cents per share (with...
(BAX) Baxter International to Recall Infusion Pumps
Medical product giant Baxter International Inc. (BAX) has decided to recall all of its Colleague infusion pumps in the U.S. over the next two years. The decision is based on the final order of the U.S. Food...
(BAX) Baxter International – Bear of the Day
Baxter International (BAX) currently derives 58% of total revenues from international operations. Therefore, a strengthening U.S. dollar can hurt the company’s international revenues and subsequently...
(BAX) Baxter International Recalls Products
Baxter International Inc. (BAX) has recently initiated a voluntary recall of all lots of its Hylenex recombinant as a result of glass particles found in vials of the product. Hylenex increases the absorption...
(BAX) Baxter International – Bear of the Day
We believe that Baxter International’s (BAX) focus on life-sustaining products insulates its results from economic downturns. The company has a strong product pipeline, with a number of promising products...
(BAX) Baxter International Analyst Downgrades the Stock
We recently downgraded Baxter International Inc. (BAX) to “Underperform” with a target price of $41 based on a P/E of roughly 10.4x our fiscal 2010 EPS estimate of $3.95. The company faces significant...
(BDX) Becton, Dickinson and Company Earnings Tops Estimate
Becton, Dickinson and Company (BDX) reported second quarter fiscal 2010 earnings per share of $1.27, surpassing the Zacks Consensus Estimate of $1.23 and the year-ago earnings of $1.17.
Sales
(BAX) Baxter International Posts Encouraging Clinical Study Results
Baxter International Inc. (BAX) recently produced encouraging results of its 18-month Phase II clinical study of GAMMAGARD LIQUID and GAMMAGARD S/D (Immune Globulin Intravenous [Human]) for mild-to-moderate...
(BAX) Baxter International Receives FDA Approval for TachoSil
Baxter International Inc. (BAX) and Nycomed recently received the U.S. Food and Drug Administration (FDA) approval of TachoSil, an absorbable fibrin sealant patch that can be used in addition to hemostasis...
(HAE) Haemonetics Enters New Agreement
Haemonetics Corp. (HAE) recently entered a new reagent development and supply agreement with Quotient Biodiagnostics Group and its wholly-owned subsidiary Alba Bioscience Limited. Per the agreement, Haemonetics...
(BAX) Baxter International Posts Flu Vaccine Trial Results
Recently, Baxter International Inc. (BAX) announced data from a late-stage study for its flu vaccine candidate Preflucel. The candidate provided a 71% protection rate against all strains of the flu. Furthermore,...
(HAE) Haemonetics Receives U.S. Food and Drug Administration Approval
Haemonetics Corp. (HAE) recently received the U.S. Food and Drug Administration (FDA) approval for its expanded nomogram to collect two Red Blood Cells on the Cymbal Automated Blood Collection System from...
(BDX) Becton, Dickinson and Company Recalls Catheters
Becton, Dickinson and Company (BDX) recently started expanding the recall of its catheters as a result of a manufacturing problem that could cause fatal embolisms or blood leakage. Becton is recalling its...
(BAX) Baxter International Downgraded to Neutral
We recently downgraded Baxter International Inc. (BAX) to Neutral. The stock was assigned a target price of $59 based on an approximate P/E multiple of 13.9x our fiscal 2010 earnings estimate of $4.25.
Baxter...
(HAE) Haemonetics Corporation Misses Earnings Estimates
Haemonetics Corporation (HAE) reported third quarter fiscal 2010 earnings per share of 71 cents, missing the Zacks Consensus Estimate of 72 cents. Earnings in the year-ago quarter were 63 cents.
The...
(BDX) Becton, Dickinson and Company Beats Expectations – Bumps Estimates
We recently reiterated our Neutral rating on Becton, Dickinson and Company (BDX) with a target price of $78 based on a P/E of approximately 15.3x our fiscal 2010 EPS estimate of $5.10.
Becton recently...
(BDX) Becton Dickinson and Company Surpasses Consensus Estimates
Becton, Dickinson and Company (BDX) reported first quarter fiscal 2010 earnings per share of $1.30, surpassing the Zacks Consensus Estimate of $1.20 and the year-ago earnings of $1.25.
Total...
(BAX) Baxter International Reports Earnings In-Line
Baxter International Inc. (BAX) reported financial results for the fourth quarter and full fiscal 2009. For the fourth quarter, earnings per share were $1.03, in line with the Zacks Consensus Estimate and...
(HAE) Haemonetics Files Patent Infringement Lawsuit Against Fenwal Inc
Haemonetics Corporation (HAE) has recently filed a new lawsuit against Fenwal Inc. regarding the latter’s continued patent infringement with the release of its red cell collection kits. Fenwal allegedly...
(BDX) Becton, Dickinson and Co Receives FDA Clearance
Becton, Dickinson and Co. (BDX) recently announced that BD Diagnostics, a segment of BDX, has received U.S. Food and Drug Administration (FDA) clearance to utilize its BD ProbeTec Chlamydia trachomatis (CT)...